Cargando…

Mechanisms that allow vaccination against an oncolytic vesicular stomatitis virus-encoded transgene to enhance safety without abrogating oncolysis

Vaccination can prevent viral infections via virus-specific T cells, among other mechanisms. A goal of oncolytic virotherapy is replication of oncolytic viruses (OVs) in tumors, so pre-existing T cell immunity against an OV-encoded transgene would seem counterproductive. We developed a treatment for...

Descripción completa

Detalles Bibliográficos
Autores principales:	AuYeung, Amanda W. K., Mould, Robert C., Stegelmeier, Ashley A., van Vloten, Jacob P., Karimi, Khalil, Woods, J. Paul, Petrik, James J., Wood, Geoffrey A., Bridle, Byram W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316323/ https://www.ncbi.nlm.nih.gov/pubmed/34315959 http://dx.doi.org/10.1038/s41598-021-94483-z

Ejemplares similares

Characterization of the Impact of Oncolytic Vesicular Stomatitis Virus on the Trafficking, Phenotype, and Antigen Presentation Potential of Neutrophils and Their Ability to Acquire a Non-Structural Viral Protein
por: Stegelmeier, Ashley A., et al.
Publicado: (2020)

Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8(+) T-cell responses to anticancer vaccines
por: Bridle, Byram W, et al.
Publicado: (2013)

Enhancing Immune Responses to Cancer Vaccines Using Multi-Site Injections
por: Mould, Robert C., et al.
Publicado: (2017)

The Role of Neutrophils in Oncolytic Orf Virus-Mediated Cancer Immunotherapy
por: Minott, Jessica A., et al.
Publicado: (2022)

Cell Cycle Progression or Translation Control Is Not Essential for Vesicular Stomatitis Virus Oncolysis of Hepatocellular Carcinoma
por: Marozin, Sabrina, et al.
Publicado: (2010)

Myeloid Cells during Viral Infections and Inflammation
por: Stegelmeier, Ashley A., et al.
Publicado: (2019)

Using a Prime-Boost Vaccination Strategy That Proved Effective for High Resolution Epitope Mapping to Characterize the Elusive Immunogenicity of Survivin
por: Mould, Robert C., et al.
Publicado: (2021)

Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity
por: Olagnier, David, et al.
Publicado: (2017)

Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer
por: van Vloten, Jacob P, et al.
Publicado: (2022)

Use of Precision-Cut Lung Slices as an Ex Vivo Tool for Evaluating Viruses and Viral Vectors for Gene and Oncolytic Therapy
por: Rosales Gerpe, María C., et al.
Publicado: (2018)

Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy
por: Simovic, Boris, et al.
Publicado: (2015)

Quantifying Antibody Responses Induced by Antigen-Agnostic Immunotherapies
por: van Vloten, Jacob P., et al.
Publicado: (2019)

Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy
por: Muik, Alexander, et al.
Publicado: (2012)

Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus
por: Hastie, Eric, et al.
Publicado: (2016)

Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells
por: Goad, Dakota W., et al.
Publicado: (2023)

Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer
por: Heiber, Joshua F., et al.
Publicado: (2011)

Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activity
por: Bourgeois-Daigneault, Marie-Claude, et al.
Publicado: (2016)

Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers
por: Nagalo, Bolni Marius, et al.
Publicado: (2020)

Diversity in responses to oncolytic Lassa-vesicular stomatitis virus in patient-derived glioblastoma cells
por: Kim, Teddy E., et al.
Publicado: (2021)

Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions
por: Holbrook, Molly C., et al.
Publicado: (2021)

Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus
por: Goad, Dakota W., et al.
Publicado: (2021)

Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models
por: Le Boeuf, Fabrice, et al.
Publicado: (2017)

Experimental Evolution of an Oncolytic Vesicular Stomatitis Virus with Increased Selectivity for p53-Deficient Cells
por: Garijo, Raquel, et al.
Publicado: (2014)

N-Myc expression enhances the oncolytic effects of vesicular stomatitis virus in human neuroblastoma cells
por: Corredor, Juan C, et al.
Publicado: (2016)

Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a “Hammer” and “Anvil”
por: Melzer, Michael Karl, et al.
Publicado: (2017)

Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants
por: Pipperger, Lisa, et al.
Publicado: (2021)

SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus
por: Alkayyal, Almohanad A., et al.
Publicado: (2023)

Hydrodynamic characterization of a vesicular stomatitis virus-based oncolytic virus using analytical ultracentrifugation
por: Wawra, Simon, et al.
Publicado: (2023)

Quantifying Antigen-Specific T Cell Responses When Using Antigen-Agnostic Immunotherapies
por: van Vloten, Jacob P., et al.
Publicado: (2019)

Type I Interferon-Mediated Regulation of Antiviral Capabilities of Neutrophils
por: Stegelmeier, Ashley A., et al.
Publicado: (2021)

Potent systemic therapy of Multiple Myeloma utilizing Oncolytic Vesicular stomatitis virus coding for Interferon-beta
por: Naik, Shruthi, et al.
Publicado: (2012)

In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
por: Jenner, Adrianne L, et al.
Publicado: (2021)

Oncolytic virotherapy with SOCS3 enhances viral replicative potency and oncolysis for gastric cancer
por: Matsumura, Shuichi, et al.
Publicado: (2021)

Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment
por: Wang, Lihong, et al.
Publicado: (2022)

Aphthæ, or Vesicular Stomatitis of the Horse
por: Hutcheon, D.
Publicado: (1898)

Generation of a Tumor-Specific Chemokine Gradient Using Oncolytic Vesicular Stomatitis Virus Encoding CXCL9
por: Eckert, Elizabeth C., et al.
Publicado: (2019)

Correction: In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
Publicado: (2021)

Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer
por: Rangsitratkul, Coby, et al.
Publicado: (2022)

RIG‐I‐mediated innate immune signaling in tumors reduces the therapeutic effect of oncolytic vesicular stomatitis virus
por: Zhang, Pengfei, et al.
Publicado: (2022)

Combination of Oncolytic Measles Virus and Ursolic Acid Synergistically Induces Oncolysis of Hepatocellular Carcinoma Cells
por: Liu, Ching-Hsuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jjf6i7gaubo37v1v33fugg91qe